Trial Profile
A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Tirasemtiv (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Registrational
- Acronyms VIGOR-ALS
- Sponsors Cytokinetics
- 18 Dec 2018 Status changed from active, no longer recruiting to completed.
- 16 Nov 2018 This trial has been completed in Spain on 2018-10-26.
- 10 Nov 2018 This trial has been completed in Ireland on 2018-10-26.